Browsing by Subject "psoriasis"

Now showing 1 - 5 of 5
  • Thumbnail Image
    Item
    Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility
    (Nature Publishing Group, 2015-04-23) Yin, Xianyong; Low, Hui Qi; Wang, Ling; Li, Yonghong; Ellinghaus, Eva; Han, Jiali; Estivill, Xavier; Sun, Liangdan; Zuo, Xianbo; Shen, Changbing; Zhu, Caihong; Zhang, Anping; Sanchez, Fabio; Padyukov, Leonid; Catanese, Joseph J.; Krueger, Gerald G.; Duffin, Kristina Callis; Mucha, Sören; Weichenthal, Michael; Weidinger, Stephan; Lieb, Wolfgang; Foo, Jia Nee; Li, Yi; Sim, Karseng; Liany, Herty; Irwan, Ishak; Teo, Yikying; Theng, Colin T. S.; Gupta, Rashmi; Bowcock, Anne; De Jager, Philip L.; Qureshi, Abrar A.; de Bakker, Paul I. W.; Seielstad, Mark; Liao, Wilson; Ståhle, Mona; Franke, Andre; Zhang, Xuejun; Liu, Jianjun; Department of Dermatology, IU School of Medicine
    Psoriasis is a common inflammatory skin disease with complex genetics and different degrees of prevalence across ethnic populations. Here we present the largest trans-ethnic genome-wide meta-analysis (GWMA) of psoriasis in 15,369 cases and 19,517 controls of Caucasian and Chinese ancestries. We identify four novel associations at LOC144817, COG6, RUNX1 and TP63, as well as three novel secondary associations within IFIH1 and IL12B. Fine-mapping analysis of MHC region demonstrates an important role for all three HLA class I genes and a complex and heterogeneous pattern of HLA associations between Caucasian and Chinese populations. Further, trans-ethnic comparison suggests population-specific effect or allelic heterogeneity for 11 loci. These population-specific effects contribute significantly to the ethnic diversity of psoriasis prevalence. This study not only provides novel biological insights into the involvement of immune and keratinocyte development mechanism, but also demonstrates a complex and heterogeneous genetic architecture of psoriasis susceptibility across ethnic populations.
  • Thumbnail Image
    Item
    National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1
    (Elsevier, 2020) Gelfand, Joel M.; Armstrong, April W.; Bell, Stacie; Anesi, George L.; Blauvelt, Andrew; Calabrese, Cassandra; Dommasch, Erica D.; Feldman, Steve R.; Gladman, Dafna; Kircik, Leon; Lebwohl, Mark; Lo Re, Vincent, III; Martin, George; Merola, Joseph F.; Scher, Jose U.; Schwartzman, Sergio; Treat, James R.; Van Voorhees, Abby S.; Ellebrecht, Christoph T.; Fenner, Justine; Ocon, Anthony; Syed, Maha N.; Weinstein, Erica J.; Smith, Jessica; Gondo, George; Heydon, Sue; Koons, Samantha; Ritchlin, Christopher T.; Medicine, School of Medicine
    Objective To provide guidance about management of psoriatic disease during the coronavirus disease 2019 (COVID-19) pandemic. Study design A task force (TF) of 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care was convened. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis Foundation (NPF) staff. Clinical questions relevant to the psoriatic disease community were informed by questions received by the NPF. A Delphi process was conducted. Results The TF approved 22 guidance statements. The average of the votes was within the category of agreement for all statements. All guidance statements proposed were recommended, 9 with high consensus and 13 with moderate consensus. Limitations The evidence behind many guidance statements is limited in quality. Conclusion These statements provide guidance for the management of patients with psoriatic disease on topics ranging from how the disease and its treatments impact COVID-19 risk and outcome, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with severe acute respiratory syndrome coronavirus 2 and what they should do if they develop COVID-19. The guidance is intended to be a living document that will be updated by the TF as data emerge.
  • Thumbnail Image
    Item
    National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments
    (Elsevier, 2021-05) Gelfand, Joel M.; Armstrong, April W.; Bell, Stacie; Anesi, George L.; Blauvelt, Andrew; Calabrese, Cassandra; Dommasch, Erica D.; Feldman, Steven R.; Gladman, Dafna; Kircik, Leon; Lebwohl, Mark; Lo Re, Vincent, III; Martin, George; Merola, Joseph F.; Scher, Jose U.; Schwartzman, Sergio; Treat, James R.; Van Voorhees, Abby S.; Ellebrecht, Christoph T.; Fenner, Justine; Ocon, Anthony; Syed, Maha N.; Weinstein, Erica J.; Gondo, George; Heydon, Sue; Koons, Samantha; Ritchlin, Christopher T.; Dermatology, School of Medicine
    Objective To update guidance regarding the management of psoriatic disease during the COVID-19 pandemic. Study Design The task force (TF) includes 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis Foundation staff. Clinical questions relevant to the psoriatic disease community were informed by inquiries received by the National Psoriasis Foundation. A Delphi process was conducted. Results The TF updated evidence for the original 22 statements and added 5 new recommendations. The average of the votes was within the category of agreement for all statements, 13 with high consensus and 14 with moderate consensus. Limitations The evidence behind many guidance statements is variable in quality and/or quantity. Conclusions These statements provide guidance for the treatment of patients with psoriatic disease on topics including how the disease and its treatments affect COVID-19 risk, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with severe acute respiratory syndrome coronavirus 2 (including novel vaccination), and what they should do if they develop COVID-19. The guidance is a living document that is continuously updated by the TF as data emerge.
  • Thumbnail Image
    Item
    Plasma levels of tumour necrosis factor‐α and adiponectin can differentiate patients with psoriatic arthritis from those with psoriasis
    (Wiley, 2019-08) Johnson, C. M.; Fitch, K.; Merola, J. F.; Han, J.; Qureshi, A. A.; Li, W.-Q.; Epidemiology, School of Public Health
  • Thumbnail Image
    Item
    The association between obesity and efficacy of psoriasis therapies: An expert consensus panel
    (Elsevier, 2024) Burshtein, Joshua; Armstrong, April; Chow, May; DeBusk, Lauren; Glick, Brad; Gottlieb, Alice B.; Stein Gold, Linda; Korman, Neil J.; Lio, Peter; Merola, Joseph; Rosmarin, David; Rosenberg, Angela; Van Voorhees, Abby; Lebwohl, Mark; Dermatology, School of Medicine
    Background Psoriasis is a chronic inflammatory skin disease often associated with obesity. Psoriasis therapies may be less effective in patients with obese. The purpose of this expert consensus panel is to evaluate the relationship between obesity and efficacy of psoriasis therapies, thereby optimizing patient care. Methods A comprehensive literature search was completed on July 19, 2024, using the keywords “psoriasis,” “obesity,” “efficacy,” “treatments,” and “therapies.” A panel of 11 dermatologists with significant expertise in treatment of psoriasis gathered to review the articles and create consensus statements. A modified Delphi process was used to approve each statement and a strength of recommendation was assigned. Results The literature search produced 500 articles. A screening of the studies resulted in 22 articles that met criteria. The panel unanimously voted to adopt 10 consensus statements and recommendations, 6 were given a strength of “A,” 2 were given a strength of “B,” and 2 were given a strength of “C.” Conclusion Psoriasis and obesity have a strong association. Obesity decreases efficacy of biologics and may decrease efficacy and potentiate side effects of conventional therapies. It also impacts drug survival. Weight control is a vital component of caring for patients with psoriasis and the number of therapeutic options available is rising.